ClinicalTrials.gg
CompletedNCT03031119Updated Sep 6, 2017

Multiple Ascending Dose and DDI Study

A Phase 1 interventional study of Placebo and PF-06835919 in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Pfizer.

Enrollment
6th of 15
62 · median 48
Started
2017
with 2 others
Phase 1
9 of 16
none open now
Registered
4th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2017, is one of 9 in phase 1, and was the 4th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer as a file.
02

Study summary

Part A will investigate the safety, tolerability, PK and PD of PF-06835919 administered for 14 days in a multiple ascending dose design. Part B will assess the effect of PF-06835919 co-administration at low and high doses on the PK of atorvastatin in a single cohort.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • nonalcoholic steatohepatitis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and females (nonchildbearing potential)
  • 18 to 55 years old
  • 17.5 to 30.5

Exclusion criteria

Exclusion Criteria:

  • Known hereditary fructose intolerance or fructose malabsorption disorder (Part A)
  • Statin intolerance (Part B)
  • Unable to consume high fructose syrup-containing beverage with each meal while in the unit (Part A)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Tablets administered once or twice daily, with food, in Part A for 14 days.

    Drug: Placebo

  • Experimental
    PF-06835919

    Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.

    Drug: PF-06835919 · Drug: atorvastatin

  • Experimental
    atorvastatin

    In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.

    Drug: PF-06835919 · Drug: atorvastatin

Interventions

  • DrugPlacebo

    Tablets administered once or twice daily, with food, in Part A.

  • Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.

  • In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    Part A

    Time frame: Screening to Day 24

  2. Number of Participants With Clinical Laboratory Abnormalities

    Part A

    Time frame: Day -2 to Day 24

  3. Change from baseline in vital signs

    Part A

    Time frame: Day -1 to Day 24

  4. Change from baseline in 12-lead electrocardiogram

    Part A

    Time frame: Day -1 to Day 24

  5. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day -1 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day 3 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  7. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day 7 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  8. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day -1 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  9. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day 3 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  10. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day 7 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  11. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 3 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  12. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  13. Maximum Observed Plasma Concentration (Cmax) on Day -1 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  14. Maximum Observed Plasma Concentration (Cmax) on Day 3 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  15. Maximum Observed Plasma Concentration (Cmax) on Day 7 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  16. Plasma Decay Half-Life (t1/2) on Day -1 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  17. Plasma Decay Half-Life (t1/2) on Day 3 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

  18. Plasma Decay Half-Life (t1/2) on Day 7 of atorvastatin and 2 active metabolites

    Part B

    Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) on Day 1 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax) on Day 7 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  3. Maximum Observed Plasma Concentration (Cmax) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48, and 72 hours post-dose

  4. Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 1 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  5. Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  7. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  9. Apparent Oral Clearance (CL/F) on Day 7 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  10. Apparent Oral Clearance (CL/F) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  11. Minimum Observed Plasma Trough Concentration (Cmin) on Day 7 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  12. Minimum Observed Plasma Trough Concentration (Cmin) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  13. Accumulation Ratio (Rac) on Day 7 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  14. Accumulation Ratio (Rac) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  15. Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) on Day 7 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

  16. Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  17. Plasma Decay Half-Life (t1/2) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  18. Apparent Volume of Distribution (Vz/F) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  19. Cumulative Amount of Drug Recovered Unchanged in Urine (Ae) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  20. Percent Cumulative Amount of Drug Recovered Unchanged in Urine (Ae%) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  21. Renal Clearance (CLr) on Day 14 Part A

    Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose

  22. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    Part B

    Time frame: Screening to Day 18

  23. Number of Participants With Clinical Laboratory Abnormalities

    Part B

    Time frame: Day -2 to Day 18

  24. Change from Baseline in Vital Signs

    Part B

    Time frame: Day -2 to Day 18

  25. Change from baseline in 12-lead electrocardiogram

    Part B

    Time frame: Day -2 to Day 18

  26. Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 7 Part A

    Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose

07

Study locations

1 site
  • Pfizer Clinical Research Unit
    Brussels, B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jul 2017, 6 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2017
First posted
Jan 25, 2017
StartActual
Jan 2017
Primary completionActual
Jul 2017
CompletionActual
Jul 2017
Last update
Sep 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03031119
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 25, 2017
Start date
Jan 2017
Primary completion
Jul 2017
Completion
Jul 2017
Last update
Sep 6, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-06835919 · Atorvastatin

Start the discussion